A study to evaluate the effect of a food containing Curcuma longa on liver function

A study to evaluate the effect of a food containing Curcuma longa on liver function - A study to evaluate the effect of a food containing Curcuma longa on liver function

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027489

Enrollment

Registered

2017-05-25

Start date

2014-05-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Oral ingestion of the test product containing low dose of Curcuma longa (5 tablets per a day

8 weeks) Oral ingestion of the test product containing high dose of Curcuma longa (5 tablets per a day

8 weeks) Oral ingestion of the test product not containing Curcuma longa (5 tablets per a day

8 weeks)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Males and females from 20 to 64 years of age (2) Participants whose AST levels are <40 U/L and ALT levels are <45 U/L based on the results of preliminary examination (3) Participants who have a drinking habit (>=5 days a week) (4) Participants whose BMI are >=18 and <30 based on the results of preliminary examination (5) ALT levels were top 48 out of the participants applying to the criteria (1) - (4)

Exclusion criteria

Exclusion criteria: (1) Participants who consecutively intake pharmaceutical or healthcare food which is possible to influence liver function (2) Participants who consecutively intake pharmaceutical or healthcare food including Curcuma longa (3) Participants who are judged as unsuitable for the study based on the results of lifestyle questionnaire (4) Participants having possibilities for emerging allergy related to the study (5) Participants having a disease requiring regular medication or a history of serious diseases for which medication was required (6) Participants who are judged as unsuitable for the study based on the results of clinical and physical examination on preliminary examination (7) Participants who have participated in other clinical studies (8) Participants who intend to become pregnant or lactating (9) Subjects judged as unsuitable for the study by the investigator for other reasons

Design outcomes

Primary

Measure	Time frame
1. Aspartate aminotransferase (AST) at 0, 4, 8 weeks in the intervention and 4 weeks after the intervention. 2. Alanine aminotransferase (ALT) at 0, 4, 8 weeks in the intervention and 4 weeks after the intervention. 3. Gammma glutamyltransferase (Gammma-GTP) at 0, 4, 8 weeks in the intervention and 4 weeks after the intervention.	—

Secondary

Measure	Time frame
1.Questionnaire survey (POMS-Brief) at 0, 4, 8 weeks in the intervention and 4 weeks after the intervention.	—

Countries

Japan

Contacts

Public ContactKawasaki Kengo

House Wellness Foods Corporation Research and Development Institute

Kawasaki_Kengo@house-wf.co.jp072-778-1127

Outcome results